Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Jul 18;13(14):4191.
doi: 10.3390/jcm13144191.

Antiphospholipid Syndrome: Insights into Molecular Mechanisms and Clinical Manifestations

Alessandra Ida Celia  1 , Mattia Galli  2   3 , Silvia Mancuso  1 , Cristiano Alessandri  1 , Giacomo Frati  2   4 , Sebastiano Sciarretta  2   4 , Fabrizio Conti  1
Affiliations
Review

Antiphospholipid Syndrome: Insights into Molecular Mechanisms and Clinical Manifestations

Alessandra Ida Celia et al. J Clin Med. .

Abstract

Antiphospholipid syndrome (APS) is a complex systemic autoimmune disorder characterized by a hypercoagulable state, leading to severe vascular thrombosis and obstetric complications. The 2023 ACR/EULAR guidelines have revolutionized the classification and understanding of APS, introducing broader diagnostic criteria that encompass previously overlooked cardiac, renal, and hematologic manifestations. Despite these advancements, diagnosing APS remains particularly challenging in seronegative patients, where traditional tests fail, yet clinical symptoms persist. Emerging non-criteria antiphospholipid antibodies offer promising new diagnostic and management avenues for these patients. Managing APS involves a strategic balance of cardiovascular risk mitigation and long-term anticoagulation therapy, though the use of direct oral anticoagulants remains contentious due to varying efficacy and safety profiles. This article delves into the intricate pathogenesis of APS, explores the latest classification criteria, and evaluates cutting-edge diagnostic tools and therapeutic strategies.

Keywords: antiphospholipid antibodies; endothelial dysfunction; immunothrombosis.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflicts of interest.

References

    1. Chaturvedi S., McCrae K.R. Diagnosis and management of the antiphospholipid syndrome. Blood Rev. 2017;31:406–417. doi: 10.1016/j.blre.2017.07.006. - DOI - PMC - PubMed
    1. Gómez-Puerta J.A., Cervera R. Diagnosis and classification of the antiphospholipid syndrome. J. Autoimmun. 2014;48–49:20–25. doi: 10.1016/j.jaut.2014.01.006. - DOI - PubMed
    1. Comellas-Kirkerup L., Hernández-Molina G., Cabral A.R. Antiphospholipid-associated thrombocytopenia or autoimmune hemolytic anemia in patients with or without definite primary antiphospholipid syndrome according to the Sapporo revised classification criteria: A 6-year follow-up study. Blood. 2010;116:3058–3063. doi: 10.1182/blood-2010-05-283507. - DOI - PubMed
    1. Pons-Estel G.J., Andreoli L., Scanzi F., Cervera R., Tincani A. The antiphospholipid syndrome in patients with systemic lupus erythematosus. J. Autoimmun. 2017;76:10–20. doi: 10.1016/j.jaut.2016.10.004. - DOI - PubMed
    1. Cervera R., Asherson R.A., Acevedo M.L., Gómez-Puerta J.A., Espinosa G., De La Red G., Gil V., Ramos-Casals M., García-Carrasco M., Ingelmo M., et al. Antiphospholipid syndrome associated with infections: Clinical and microbiological characteristics of 100 patients. Ann. Rheum. Dis. 2004;63:1312–1317. doi: 10.1136/ard.2003.014175. - DOI - PMC - PubMed

LinkOut - more resources